These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26244666)

  • 21. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome.
    Miller P; Kidwell KM; Thomas D; Sabel M; Rae JM; Hayes DF; Hudson BI; El-Ashry D; Lippman ME
    Breast Cancer Res Treat; 2017 Nov; 166(1):85-94. PubMed ID: 28717852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
    Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
    Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
    Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers.
    Park S; Park HS; Koo JS; Yang WI; Kim SI; Park BW
    Breast Cancer Res Treat; 2012 May; 133(1):311-20. PubMed ID: 22231421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.
    Hartog H; Horlings HM; van der Vegt B; Kreike B; Ajouaou A; van de Vijver MJ; Marike Boezen H; de Bock GH; van der Graaf WT; Wesseling J
    Breast Cancer Res Treat; 2011 Oct; 129(3):725-36. PubMed ID: 21107683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
    Liu YR; Jiang YZ; Yu KD; Shao ZM
    Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL;
    J Clin Oncol; 2007 May; 25(15):2006-11. PubMed ID: 17452676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.
    Synnestvedt M; Borgen E; Schlichting E; Schirmer CB; Renolen A; Giercksky KE; Nesland JM; Naume B
    Breast Cancer Res Treat; 2013 Apr; 138(2):485-97. PubMed ID: 23456230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
    Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic effect of estrogen receptor status across age in primary breast cancer.
    Bentzon N; Düring M; Rasmussen BB; Mouridsen H; Kroman N
    Int J Cancer; 2008 Mar; 122(5):1089-94. PubMed ID: 17960621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
    Gulbahce HE; Sweeney C; Surowiecka M; Knapp D; Varghese L; Blair CK
    Hum Pathol; 2013 Nov; 44(11):2427-31. PubMed ID: 23998430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stem cell biomarker ALDH1A1 in breast cancer shows an association with prognosis and clinicopathological variables that is highly cut-off dependent.
    Sjöström M; Hartman L; Honeth G; Grabau D; Malmström P; Hegardt C; Fernö M; Niméus E
    J Clin Pathol; 2015 Dec; 68(12):1012-9. PubMed ID: 26175266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expressions of MAP2K4 and estrogen receptor and their clinical significance in invasive breast cancer].
    Liu S; Liu YY; Li R
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 37(4):488-493. PubMed ID: 28446401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.
    Markkula A; Simonsson M; Rosendahl AH; Gaber A; Ingvar C; Rose C; Jernström H
    Int J Cancer; 2014 Oct; 135(8):1898-910. PubMed ID: 24599585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors.
    Yan Y; Penner CC; Skliris GP; Cooper C; Nugent Z; Blanchard A; Hamedani MK; Wang X; Myal Y; Murphy LC; Leygue E
    J Cancer Res Clin Oncol; 2013 Oct; 139(10):1637-47. PubMed ID: 23907597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.